Before the era of HER2-directed therapy, HER2 gene amplification was known to be otherwise associated with shorter disease-free and overall survival in breast cancers, as per a 1987 study conducted by Slamon et al. [44]. This evidence concerns the gene ERBB2 and breast cancer.